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ABSTRACT
Vibrio cholerae, the etiological agent of the
diarrheal illness cholera, can kill an infected adult in
24 h. V.cholerae lives as an autochthonous microbe
in estuaries, rivers and coastal waters. A better
understanding of its metabolic pathways will assist
the development of more effective treatments and
will provide a deeper understanding of how this
bacterium persists in natural aquatic habitats.
Using the completed V.cholerae genome sequence
and PathoLogic software, we created VchoCyc, a
pathway-genome database that predicted 171 likely
metabolic pathways in the bacterium. We report
here experimental evidence supporting the compu-
tationally predicted pathways. The evidence comes
from microarray gene expression studies of
V.cholerae in the stools of three cholera patients
[D. S. Merrell, S. M. Butler, F. Qadri, N. A. Dolganov,
A. Alam, M. B. Cohen, S. B. Calderwood,
G. K. Schoolnik and A. Camilli (2002) Nature, 417,
642–645.], from gene expression studies in minimal
growth conditions and LB rich medium, and from
clinical tests that identify V.cholerae. Expression
data provide evidence supporting 92 (53%) of the
171 pathways. The clinical tests provide evidence
supporting seven pathways, with six pathways
supported by both methods. VchoCyc provides
biologists with a useful tool for analyzing this orga-
nism’s metabolic and genomic information, which
couldleadtopotentialinsightsintonewanti-bacterial
agents. VchoCyc is available in the BioCyc database
collection (http://BioCyc.org).
INTRODUCTION
Vibrio cholerae causes cholera, a diarrheal disease that
occurs most frequently in the form of severe epidemics (1).
There have been seven pandemics worldwide since 1817;
the current pandemic started in 1961 and affects six contin-
ents (2). When untreated, an infected adult can be killed in
24 h (3). V.cholerae is a Gram-negative, facultative anaerobic
bacterium, and its most unusual feature is that it has two dis-
tinctive lifestyles: as a pathogen living in the human intestine
and as a bacterium well-adapted to survive in various niches
in aquatic habitats, including symbiotic and commensal asso-
ciations with phytoplankton and zooplankton, respectively
(2). As a result, it is logical to speculate that its metabolic
repertoire has a capacity to transport and assimilate nutrients
from these diverse environments. We are interested in pre-
dicting the metabolic pathways of this organism to better
understand its biochemistry and obtain potential insights or
targets for new anti-bacterial agents. The genome sequence
of V.cholerae (strain N16961) provides a new foundation
for the study of this organism’s pathological and environ-
mental characteristics (4). Using the V.cholerae genome
sequence and the PathoLogic software (5,6) we created
VchoCyc (pronounced Vee-koh-sike), a pathway-genome
database (PGDB) that predicts V.cholerae’s likely metabolic
pathways. Here, we describe VchoCyc and report experi-
mental evidence supporting the computationally predicted
pathways. Experimental results come from microarray gene
expression studies performed with V.cholerae isolated from
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doi:10.1093/nar/gkl310three patients, as well as the same type strain grown in min-
imal media or LB rich medium, and from known nutrient
requirements employed in clinical tests used to distinguish
V.cholerae from other species.
MATERIALS AND METHODS
VchoCyc Generation
The PathoLogic software that we used to generate VchoCyc
is described in previous papers (5–9). We describe here only
the additional steps in the creation of VchoCyc.
Since EC numbers were not available in the GenBank
annotation ﬁle used (4), PathoLogic matched the V.cholerae
protein names in a table that contains enzyme names from
the MetaCyc and Enzyme databases (9). In those cases
where there is an unambiguous match of the enzyme name,
we accept the PathoLogic assignment of the enzyme to a
reaction. In those cases where there is an ambiguous match
or a probable enzyme, we manually perform searches in
additional online sources such as UniProt and Medline to
determine the reaction(s) that the enzyme catalyzes. After the
that the enzyme catalyzes. After the name matching process
is complete, PathoLogic will import metabolic pathways
from MetaCyc into the new PGDB by matching the biochem-
ical reactions for which enzymes have been identiﬁed against
MetaCyc pathways (9). PathoLogic is intended to provide a
ﬁrst-pass pathway analysis. It is conservative in that it errs
more on the side of false-positive pathway predictions than
on the side of false-negative predictions (7). After a manual
review of predicted pathways by the user to eliminate suspec-
ted false-positive pathways, VchoCyc is initially generated.
After generating the VchoCyc database, not all reactions in
the predicted pathways have enzymes assigned. When no
enzyme is assigned to a reaction, we have a missing enzyme
or pathway hole in VchoCyc. The pathway hole ﬁller pro-
gram, described in an earlier paper (10), identiﬁes candidate
enzymes for ﬁlling pathway holes. The program uses a set of
sequences encoding the required activity in other genomes to
identify candidate proteins in the genome of interest, in addi-
tion to genomic context (such as the candidate enzyme being
in the same operon as another gene in the pathway) to deter-
mine the probability that a candidate enzyme has the required
function.
Literature on VchoCyc pathways
A comparison of known pathways of V.cholerae documented
in the literature with those computationally predicted in
VchoCyc would provide a measure of the validity of the pre-
dictions. Unfortunately, there are almost no fully character-
ized pathways in V.cholerae. The best studied V.cholerae
pathway is the vibriobactin biosynthesis pathway, which is
also not completely characterized. Part of this pathway was
predicted in VchoCyc under the name ‘enterobactin path-
way’, and more details are described in the results section.
Validation of VchoCyc with the clinical tests of
V.cholerae
Clinical tests used to diagnose whether a patient is infected
by V.cholerae specify known clinical tests for this organism
(11). These tests can be used to evaluate VchoCyc’s predic-
tions. Each nutrient that can support V.cholerae growth must
enter the cell either by diffusion or by an active transport
mechanism. Once inside the cell it must either be degraded
by catabolic pathways/reactions, or used as a substrate to syn-
thesize other metabolites. Thus, the corresponding transport-
ers and metabolic pathways/reactions should be present in
VchoCyc. In contrast, if V.cholerae cannot use a nutrient,
either the transporter system for the uptake of this nutrient
and/or the corresponding pathways/reactions should be miss-
ing from VchoCyc. We compared clinical tests data and
VchoCyc to determine whether VchoCyc’s predictions are
consistent with the known data.
V.cholerae microarray gene expression data: patient
samples
Microarray gene expression data for V.cholerae isolated
from the stools of three cholera patients were obtained from
glass-spotted DNA amplicon arrays encompassing 90% of
the identiﬁed open reading frames of this organism (4), and
they are available from the Stanford Microarray Database
(http://genome-www5.stanford.edu/MicroArray/SMD/). These
expression data document the metabolic repertoire of the
organism during the last phase of the infectious process in
man, in which cells that have detached from the ileal mucosal
surface pass through the colon in the typical rice water stool
produced by cholera patients. A detailed description of the
patient dataset is available in Ref. (12). For each of the
three patients four replicate microarray analyses were
performed, giving a total of 12 arrays. For the analyses
described here, we used the average expression of each
gene across the 12 arrays.
V.cholerae microarray gene expression data: minimal
media and LB medium
Microarray gene expression data for V.cholerae grown in
three different growth media were obtained from the Stanford
Microarray Database. Data are available for M9 minimal
medium supplemented with lactate, M9 minimal medium
supplemented with maltose and LB complex medium.
These data came from two-channel arrays, where one channel
contains the gene expression data for the organism grown in a
supplemented minimal medium while the second channel
contains data for the gene expression of the organism grown
in LB (enriched) medium—a growth condition where
genes coding for certain biosynthetic pathways should be
silent. All assays were performed with cells during mid-
exponential growth phase. Each growth condition was
assayed in four replicates; for the analyses described here,
we used the average expression of each gene in the four
replicate arrays.
Determination of a threshold for considering a gene
to be expressed
When working with the gene expression data, one needs to
determine when a gene is considered ‘expressed’. We det-
ermined a threshold for stating a gene as ‘expressed’ that is
based on the minimum expression levels of a set of essential
biosynthetic genes. Under minimal growth conditions, essen-
tial biosynthetic pathways such as those for amino acids,
Nucleic Acids Research, 2006, Vol. 34, No. 8 2439nucleotides, coenzymes, vitamins and cofactors must operate,
necessitating the expression of the encoding enzymes
involved (although not necessarily simultaneously). We
examined a set of 36 such essential biosynthetic pathways.
For each microarray, we selected a threshold value of abso-
lute expression such that a certain percentage of the reactions
in each essential biosynthetic pathway have corresponding
‘expressed’ genes (based on the requirement of 2-fold greater
expression in minimal media than in the enriched medium).
Using this threshold, an average of 42% the genes in the 36
essential biosynthetic pathways were ‘expressed’ in the four
datasets, compared with only 21% of the genes in the remain-
ing non-essential pathways.
Definition of evidence that a reaction is catalyzed and
that a pathway exists in V.cholerae
A metabolic pathway consists of a set of reactions catalyzed
by enzymes. In the simplest case, a single reaction (in a path-
way) is catalyzed by a single enzyme. For the analyses repor-
ted here, we say that there is evidence supporting a reaction
when the gene encoding an enzyme catalyzing that reaction
is expressed (as deﬁned above). If multiple enzymes can
catalyze a single reaction, expression of any one is sufﬁcient.
Similarly, we say that there is evidence supporting the exist-
ence of a pathway when a speciﬁed fraction of the reactions
in that pathway are active simultaneously (i.e. when the
genes encoding the enzymes catalyzing those reactions are
expressed simultaneously). In the results section we discuss
how modifying the speciﬁcation of this fraction affects the
results.
RESULTS
Generation of the VchoCyc PGDB
Using PathoLogic with the annotated genome of V.cholerae,
strain N16961, we have created the VchoCyc PGDB, which
is available at the BioCyc website (http://biocyc.org).
Table 1 shows the results of automatic enzyme name
matching made by PathoLogic. Curated EC numbers
have not been assigned for V.cholerae, so the matches
were made by comparing protein names. A total of 3828
proteins are predicted in the GenBank annotation for
V.cholerae. Of the 3828 proteins, 601 (16%) matched reac-
tions in the MetaCyc database. Of these 601 reactions 573
(95%) were unambiguous matches. A total of 28 (5%)
were ambiguous matches (i.e. the protein was matched to
more than one reaction in MetaCyc) and were resolved
manually. Of the remaining 3227 unmatched proteins, 284
(9%) were labeled by PathoLogic as probable enzymes,
269 (95%) of which were resolved manually: 102 were
assigned to their corresponding reactions, 167 were recog-
nized as not metabolic enzymes, and the functions of the
remaining 15 probable enzymes could not be determined.
Table 2 is a statistical summary of version 1.0 of VchoCyc.
VchoCyc contains 912 enzymatic reactions, 654 of which
have been assigned to one or more of the 639 enzymes. A
total of 258 reactions in the 171 VchoCyc pathways have
no assigned enzyme and are called pathway holes. We then
applied the pathway hole ﬁller program, which assigned
enzymes to 59 pathway holes (http://www.biomedcentral.
com/content/supplementary/1471-2105-5-76-S4.html) and
completed 14 out of the 114 incomplete pathways. For
example, the glycogen degradation pathway was completed
by the assignment of gene VCA0250, encoding alpha-
amylase, to reaction EC3.2.2.1; the de novo biosynthesis of
pyrimidine ribonucleotides pathway was completed by the
assignment of gene VC1491, encoding dihydroorotate
oxidase, to reaction EC1.3.3.1.
Figure 1 shows the distribution of the remaining pathway
holes in VchoCyc. Note that 35% of the pathways are
complete and 22% of the pathways have only one missing
reaction.
Table 1. Results of automatic matching of V.cholerae enzymes to
reactions by PathoLogic
Type of match Number of proteins
Matched by EC number 0
Matched by name 601
Ambiguous 28
Unmatched 3227
Probable enzymes 284
Table 2. VchoCyc statistics
PGDB objects Quantity
Chromosomes 2
Size (bp) 4 033 464
Genes 3950
Protein genes 3828
Enzyme genes 703
RNA genes 122
Transfer RNAs 98
Compounds 656
Polypeptides 3853
Protein complexes 39
Enzymes 639
Enzymatic Reactions 912
With enzymes in VchoCyc 654
Pathways 171
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Figure 1. Distribution of the completeness of pathways in VchoCyc, i.e. the
fractionofpathwayslackingacertainnumberofmissingreactionsasafunction
of that number. For example, 35% of the pathways in VchoCyc are complete
(i.e.lackingzeroreactions),meaningthatalltheenzymesparticipatinginthese
pathways have been identified in the genome.
2440 Nucleic Acids Research, 2006, Vol. 34, No. 8Figure 2 shows the distribution of pathway holes as a
percentage of a pathway, i.e. the percentage of the reactions
in a pathway that do not have assigned enzymes. About 16%
of the pathways in VchoCyc have 50% of the reactions
without enzymes assigned. The VchoCyc pathways are
relatively complete compared with other organisms that we
have worked with. This might be because the genome of
V.cholerae is very similar to that of Escherichia coli K-12
(4), and many pathways in MetaCyc are from E.coli.
Evidence from published literature supporting
predicted pathways
We performed a literature search to ﬁnd experimentally
veriﬁed pathways in V.cholerae to assess the agreement
between predicted and known pathways. Surprisingly, we
were not able to ﬁnd any complete V.cholerae pathways
that have been experimentally conﬁrmed. The best studied
pathway is most probably the vibriobactin biosynthesis path-
way. Vibriobactin is an iron-chelating catechol siderophore
produced by V.cholerae when iron is limited in the envir-
onment (13–15). Other catechol siderophores include
enterobactin from E.coli, yersiniabactin from Yersinia pestis
and protochelin from Azotobacer vinelandii (13–15).
Figure 3 shows the biosynthetic pathways of enterobactin
and vibriobactin (13,14). The precursor for both enterobactin
and vibriobactin is 2,3-dihydroxybenzoic acid (DHBA). Thus,
the ﬁrst committed steps in the synthesis of enterobactin or
vibriobactin lead to the synthesis of DHBA from choris-
mate. The pathway for DHBA synthesis appears to be the
same in V.cholerae and in E.coli (15), and PathoLogic iden-
tiﬁed the V.cholerae enzymes corresponding to the E.coli
DHBA-synthesizing enzymes (Figure 3). Although DHBA
is the precursor for both enterobactin and vibriobactin,
their structures differ, and their biosynthetic pathways
diverge after DHBA. Both involve multi-enzyme complexes
that are not yet fully understood (15). Enterobactin is syn-
thesized from DHBA and serine. In E.coli, among the
genes involved in this pathway are entB, entD, entE and
entF (15), but the enzymatic steps in this pathway are not
well characterized.
Vibriobactin is synthesized from DHBA, threonine and
norspermidine. Several genes have been proposed to be
involved in this process, including vibB, vibD,vibE, vibF
and vibH (15). vibB, vibD and vibE are located in a genetic
cluster (15). Evidence that these genes participate in
vibriobactin synthesis comes from mutation studies. For
example, a vibD mutant strain was able to synthesize
DHBA, but not vibriobactin; this vibriobactin defect was
complemented by vibD in a plasmid (15). Sequence compar-
ison indicates that vibD encodes phosphopantetheinyl trans-
ferase and that vibH encodes a novel non-ribosomal peptide
synthetases (15).
PathoLogic identiﬁed the pathway and genes that catalyze
DHBA synthesis from chorismate in V.cholerae. However,
it labeled this as the enterobactin pathway instead of
vibriobactin pathway because of the similarity between their
biosynthesis pathways, and because there is no vibriobactin
pathway in MetaCyc. Since the speciﬁc steps from DHBA
to enterobactin are not known in E.coli and are not in
MetaCyc (the example pathway database used to generate
VchoCyc), PathoLogic could not predict those speciﬁc
steps for V.cholerae.
Evidence from clinical tests supporting predicted
pathways
We compared VchoCyc’s metabolic predictions with 33
known clinical tests used in clinical diagnostic tests (11).
Two of these tests were excluded because different strains
give conﬂicting results for them. Of the remaining 31
V.cholerae clinical tests, VchoCyc includes a reaction or a
pathway that utilizes the substrate for 17 of them. For 16 of
these 17 clinical tests, VchoCyc identiﬁed an appropriate
transporter of the substrate and identiﬁes an enzyme or set
of enzymes to catalyze the reaction(s) utilizing the substrate
and generating the appropriate product(s), and thus is consist-
ent with the data from the clinical tests. The only inconsistent
case is D-mannose with acid production—the reaction to cata-
lyze mannose was found but not the transporter for it.
Table 3 shows the results of the comparison. We will
discuss two examples in greater detail. Clinical test data
Serine
EntC
(VC0773,VC1976)
Isochorismate synthase  
EC 5.4.4.2
Isochorismate 
2,3-dihydro-2,3-DHBA 
DHBA 
enterobactin vibriobactin 
EntB (VC0771)
EntB (VC0774) 
Isochorismatase 
EC 3.3.2.1
2,3-dihydro-2,3-DHBA 
dehydrogenase 
EC 1.3.1.28 
Threonine 
Norspermidine
Chorismate
Figure 3. Biosynthetic pathways of the iron-chelating catechol siderophores
enterobactin and vibriobactin (15).
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Figure 2. Distribution of incomplete pathways in VchoCyc based on the per-
centage of the reactions in a pathway that do not have assigned enzymes. For
example, 16% of the pathways in VchoCyc lack enzymes for 50% of their
reactions.
Nucleic Acids Research, 2006, Vol. 34, No. 8 2441suggest that V.cholerae produces acid when grown on the
sugar Trehalose. In VchoCyc, the transporter for Trehalose
(phosphoenolpyruvate-dependant phosphotransferase system,
Trehalose-speciﬁc IIBC component) is present and enzymes
that catalyze the reaction to produce acid from Trehalose
(EC 3.2.1.28 and EC 2.7.1.2) are also present. The test of
D-sorbitol with acid production is negative clinically and in
VchoCyc neither the transporter nor the reaction is present,
which is consistent with the clinical ﬁnding.
Evidence from microarray expression data supporting
predicted pathways
PathoLogic predicted 171 metabolic pathways in V.cholerae.
As described in the Materials and Methods section, for the
purpose of this analysis, we say that experimental evidence
supports the existence of a predicted pathway when a speci-
ﬁed percent of the reactions in that pathway are active simul-
taneously (i.e. the genes encoding the enzymes catalyzing
those reactions are expressed simultaneously). Below, we
consider the effect of the fraction of the reactions necessary
to determine that there is evidence supporting the existence
of a pathway.
Supplementary Table 4 shows the percent of reactions
supported by expression evidence for each predicted pathway
in each dataset. At the top of the table we see several
pathways for which there is expression evidence supporting
100% of the component reactions under all growth con-
ditions; these pathways are aspartate biosynthesis and
Table 3. Consistency between clinical tests and the computational predictions in VchoCyc
Test
a V.cholerae
(clinical tests)
b
VchoCyc
(predicted)
c
Evidence on transporter and reaction in VchoCyc
d
Urea hydrolysis 
e  Transported through simple diffusion; no reaction found
Phenylalanine deaminase  No transporter; no reaction found
Arginine, Moeller  Transported by arginine ABC transporter; no reaction found
Lysine, Moeller ++ Transported by Cadaverine/Lysine antiporter; EC4.1.1.18(VC0281)
Ornithine, Moeller ++ Transported by Putrescine-Orthinine antiporter; EC4.1.1.17 (VCA1068)
(ornithine degradation pwy)
Malonate utilization  No transporter; no reaction found
D-Glucose, acid production ++ Transported by PTS; too many pwys can do this
D-Glucose, gas production  Transported by PTS; no reaction found
D-Adonitol, acid production  N/A
f N/A
L-Arabinose, acid production  N/A N/A
Cellobiose, acid production +/ Transported by PTS; no reaction found
Dulcitol, acid production  N/A N/A
Erythritol, acid production  No transporter; no reaction found
D-Galactose, acid production ++ Transported by Galactose ABC transporter;EC2.7.1.6(VC1595)(galactose
degradation pwy)
Glycerol, acid production +/ + Transported by simple diffusion; EC2.7.1.30 (VCA0774) (many pwys)
myo-Inositol, acid production  N/A N/A
Lactose, acid production +/ No transporter; By EC3.2.1.23 (no enzyme assigned), lactose becomes to
b-D-galactose and b-D-glucose, which further produce acid (lactose
degradation IV pwy and glactose, galactoside, and glucose catabolism
Maltose, acid production ++ Transported by Maltose ABC transporter; By EC2.4.1.25 (VCA0014),
maltose becomes b-D-glucose (Glycogen biosynthesis pwy), which
further produces acid.
D-Mannitol, acid production ++ Transported by PTS system; EC 1.1.1.17 (Mannitol degradation pathway)
D-Mannose, acid production +  No transporter for Mannose; EC2.7.1.7 (GDP-mannose matabolism pwy)
Melibiose, acid production  No transporter for Melibiose; EC3.2.1.22 (VC1690) (galactose, galactoside
and glucose catabolism)
A-Methyl-D-glucoside, acid production  N/A N/A
Raffinose, acid production  N/A N/A
L-Rhamnose, acid production  N/A N/A
Salicin, acid production  N/A N/A
D-Sorbitol, acid production  N/A N/A
Sucrose, acid production ++ Transported by PTS; By EC2.4.1.13, sucrose can become fructose, which
then further produces acid.
Trehalose, acid production ++ Transported by PTS; by EC3.2.1.28 , threhalose can become b-D-glucose,
which further produces acid
D-Xylose, acid production  N/A N/A
Mucate, acid production  N/A N/A
Esculin hydrolysis  N/A N/A
Acetate utilization ++ Acetate can be transported by simple diffusion; Acetate utilization pwy
Nitrate->Nitrite ++ Transported by Nitrate Reductase; EC1.7.99.4 (VC1690) (anaerobic
respiration, electron acceptors reaction list)
aThe names of the tests.
bThe results of the tests from clinical tests.
cThe results of the tests from checking the VchoCyc database.
dThe reactions/pathways that are actually present in VchoCyc.
eSymbols:+,moststrains(generallyabout90–100%)positive;,moststrainsnegative(generallyabout0–10%positive);+/,strainscouldbepositiveornegative
(generally about 11–89% positive); N/A, the substrate in the test cannot be found in VchoCyc.
fN/A means the substrate in a clinical test is not found in VchoCyc.
2442 Nucleic Acids Research, 2006, Vol. 34, No. 8degradation, saturated fatty acid elongation, unsaturated fatty
acid elongation, glycine biosynthesis I, glycine cleavage and
the malate/aspartate shuttle pathway. At the bottom of the
table we see several pathways for which there is no expres-
sion evidence supporting any of the component reactions;
these pathways are 4-hydroxyproline degradation, Entner-
Doudoroff pathway, L-idonate degradation and tyrosine
biosynthesis II.
We now consider the effect of specifying a series of differ-
ent percents of the reactions necessary to determine that there
is evidence supporting a pathway. Figure 4 shows the percent
of pathways for which there is supporting evidence as a func-
tion of the percent of the reactions in that pathway that we
require to be active simultaneously (genes encoding enzymes
catalyzing those reactions are expressed simultaneously). For
example, if we require at least 60% of the reactions active
simultaneously, then out of the 171 pathways included in
VchoCyc, 40% (69) of the pathways have supporting evid-
ence from the microarray gene expression data for growth
in M9 + lactate medium, 61% (105) of the pathways have
supporting evidence from growth in M9 + maltose medium,
70% (97) of the pathways have supporting evidence from
data for growth in LB medium and 62% (106) of the
pathways have supporting evidence from clinical samples
from patients. Using a value of 100% (meaning that all the
reactions in a pathway must be active simultaneously), the
percents of pathways having supporting evidence are 13%
(29), 34% (59), 26% (45) and 25% (43) in M9 + lactate
medium, M9 + maltose medium, LB medium and patient
samples, respectively.
Are the reactions supported by expression evidence under
the different growth conditions, as summarized in Supple-
mentary Table 4, consistent with the expected metabolic
activity of each condition? Merrell and colleagues previously
reported on the genes that are differentially expressed in
patient samples versus LB medium (12); they found that in
patient samples there is an increase in the expression of
genes required for amino acid biosynthesis. In our analysis
of the expression evidence supporting the predicted pathways
(Supplementary Table 4), we found in both patient samples
and minimal media the evidence supporting the existence
of biosynthesis pathways for amino acids such as Valine,
Leucine, Glutamate and Alanine, as well as for nucleotides
such as de novo biosynthesis of Purine nucleotides and
de novo biosynthesis of Pyrimidine deoxyribonucleotides.
In LB rich medium, we found evidence supporting the exist-
ence of the degradation pathways for Glutamine, Ornithine,
Threonine and so on. In patients with cholera, there is
extreme ﬂuid loss; the intestines become a nutrient-poor
environment that is similar to minimal media, so it is rea-
sonable that expression evidence supporting the existence
of these biosynthesis pathways comes from these two condi-
tions. In contrast, LB medium is extremely rich in amino
acids and nucleotides; we would expect that the degradation
pathways are up regulated and that the biosynthesis pathways
are down regulated, so it is reasonable that we see expression
evidence supporting the existence of the degradation path-
ways from the LB rich medium condition.
DISCUSSION
Using Pathway Tools software, we constructed a pathway-
genome database for Vibrio cholerae from its annotated
genome. After running PathoLogic to create VchoCyc, 114
pathways had reactions that lacked one or more assigned
enzymes, for a total of 258 pathways holes. We used the
pathway hole ﬁller tool to assign 59 candidate enzymes out
of the total 258 pathway holes, which completed 14 of the
114 pathways.
In order to validate the predicted pathways, we used sev-
eral sources of evidence: (i) previously known pathways in
literature; (ii) consistency with the clinical tests; (iii) consist-
ency with microarray expression data. Vibriobactin pathway,
perhaps the best studied pathway in V.cholerae, is predicted
to be present. Among the 17 clinical tests used for the
diagnosis of V.cholerae, 16 of them are consistent with
VchoCyc.
We examined the expression evidence supporting the pres-
ence of each pathway. Using the criterion that at least 60% of
the reactions in a pathway are supported by expression evid-
ence, the expression data under the conditions in these experi-
ments provide the evidence supporting 53% (92) of the 171
pathways. We found that the reactions supported by expres-
sion evidence under the different growth conditions (patient
stool, minimal media, rich medium) are consistent with the
expected metabolic activity of each condition: in both (nutri-
ent poor) patient samples and minimal media, the evidence
supports the existence of nucleic acid and amino acid biosyn-
thesis pathways, while in rich LB medium we see expression
evidence supporting the existence of the corresponding
degradation pathways.
There are several explanations as to why a predicted path-
way would not be supported by expression evidence: (i) It is
not present in V.cholerae. (ii) It is present in V.cholerae but
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Figure 4. Percentage of pathways for which there is supporting evidence
as a function of the percent of the reactions in that pathway that we require
to be active simultaneously (i.e. enzymes catalyzing those reactions are
expressed simultaneously). M9 with lactate (diamond), M9 with maltose
(square), patient stool sample (triangle) and LB medium (circle with
dotted line).
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expressed under the conditions examined, but the pathway
does not meet our evidence criteria because an array experi-
ment measures a snapshot of a cell, while the genes encoding
the different enzymes in a pathway might be turned on and
off in a temporal manner.
Since the genome of V.cholerae is most similar to that
of E.coli K-12 (4), it is interesting to determine which
V.cholerae pathways are not shared by the two organisms.
They are both Gram-negative bacteria, but their lifestyles
and pathogenicities are quite different: E.coli mainly lives
in the large intestine of a human host and rarely causes dis-
eases for its host. In contrast, V.cholerae cannot only live
in the small intestine of its human host but also live in estu-
arine community; it causes severe diarrhea to its host. We
compared the pathways from these organisms using the
VchoCyc and EcoCyc databases available through the
BioCyc Database collection. In some cases, we can identify
the role that these unique pathways play. For example,
V.cholerae uses ectoine, the product of the ectoine synthesis
pathway, to adjust to changes in the ionic composition and
osmolarity of its estuarine environment (16). D-rhamnose,
the product of the GDP-D-rhamnose biosynthesis pathway,
is a rare 6-deoxy monosaccharide that occurs primarily in
the lipopolysaccharide of pathogenic bacteria; it is involved
in host-bacterium interactions and the establishment of
infection (17).
Little pathway information is available for V.cholerae, des-
pite it being a serious pathogen. VchoCyc can help integrate
the currently available knowledge, and it can help by pointing
to omissions in our knowledge (such as missing pathways, as
well as pathway holes). We hope and encourage the cholerae
community to adopt the VchoCyc database as a tool for shar-
ing knowledge and for suggesting promising directions for
research.
The query, visualization and editing facilities of Pathway
Tools provide extensive analysis capabilities to researchers.
The metabolic overview expression viewer allows researchers
to visualize expression data in a metabolic context, and thus
differential metabolic gene expression can be discovered eas-
ily under different conditions. Therefore, we envision that
PGDBs such as VchoCyc generated by Pathway Tools pro-
vide not only a useful platform to integrate and disseminate
knowledge about this organism, but also provide a tool that
facilitates analysis and discovery.
One might argue that we do not need computer software
like Pathway Tools to predict pathways and that a biochemist
could predict pathways just by looking at the list of annotated
genes. Prediction by hand is possible, but the question is how
accurate and complete it is. It is difﬁcult to predict pathways
accurately because some reactions are present in many path-
ways, and it is difﬁcult to be complete by hand because there
are so many known metabolic pathways to consider (see our
analysis of Helicobacter pylori metabolism in which Patho-
Logic predicted many pathways whose presence was not
recognized by H. pylori experts). Also, manual prediction
requires so much time that it is prohibitive to perform mul-
tiple manual pathway predictions for evolving annotations
of a single genome. Thus, a tool to automatically evaluate
experimental evidence supporting predicted pathways is of
practical value.
SUPPLEMENTARY DATA
Supplementary data are available at NAR Online.
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